Chinese Company Drives Global NMN Regulatory Breakthroughs in the U.S. and Australia
Nicotinamide mononucleotide (NMN) has long attracted global attention as a promising ingredient in health supplements and functional foods, due to its potential role in supporting cellular metabolism, healthy aging, and overall well-being. In recent weeks, key regulatory developments driving in major markets have brought clarity to NMN's legal status, creating new opportunities for the supplement industry. United States: FDA Restores NMN's Dietary Supplement Status On December 9, 2025, the U.S. Food and Drug Administration (FDA) published a response letter on Regulations.gov, addressing submissions by Chinese company SyncoZymes (Shanghai) Co., Ltd. regarding β-nicotinamide mononucleotide (NMN). *Image source: Regulations.gov The